Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome
February 01 2021 - 7:05AM
Business Wire
Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology
company focused on advancing novel antiviral therapies to treat
diseases associated with a viral triggered abnormal immune
response, announced today that it is entering a collaboration with
Dr. Michael Camilleri of the Mayo Clinic to explore the role of
antiviral therapy in managing Irritable Bowel Syndrome (IBS). The
first step in the collaboration is focused on designing a phase 2
proof of concept study to treat the pain associated with IBS, with
the longer-term goal of conducting the phase 2 study.
Greg Duncan, CEO stated, “We are very excited to be working with
Dr. Camilleri, a world-renowned expert in gastrointestinal
disorders. This proof-of-concept study is intended to evaluate if
IMC-1, our proprietary fixed dose antiviral combination of
famciclovir and celecoxib, can play a role in addressing the pain
associated with IBS.”
About Virios Therapeutics
Virios Therapeutics is a development-stage biotechnology company
focused on advancing novel antiviral therapies to treat diseases
associated with a viral triggered abnormal immune response, such as
fibromyalgia (“FM”). Overactive immune response related to
activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has
been postulated to be a potential root cause of chronic illnesses
such as FM, irritable bowel disease (“IBS”), chronic fatigue
syndrome and functional somatic syndrome, all of which are
characterized by a waxing and waning manifestation of disease.
While not completely understood, there is general agreement in the
medical community that activation of HSV-1 is triggered by some
form of environmental and/or health stressor. Our lead development
candidate (“IMC-1”), is a novel, proprietary, fixed dose
combination of famciclovir and celecoxib. IMC-1 represents a novel
combination antiviral therapy designed to synergistically suppress
HSV-1 activation and replication, with the end goal of reducing
viral mediated disease burden.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in
the final prospectus related to the public offering filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and Virios
Therapeutics, Inc. undertakes no duty to update such information
except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210201005242/en/
Jenny Kobin IR@Virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Sep 2023 to Sep 2024